Trastuzumab

Oncologist

Volumn 16, Issue 6, 2011, Pages 800-810

  Boekhout, Annelies H ^a   Beijnen, Jos H ^a,b,c   Schellens, Jan H M ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cardiotoxicity; Monoclonal antibody; Safety monitoring; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CANDESARTAN; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; LETROZOLE; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADVANCED CANCER; ARTICLE; ASYMPTOMATIC DISEASE; BREAST CANCER; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CHILL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; LACTATION; LOADING DRUG DOSE; MONOTHERAPY; NONHUMAN; OXYGEN SATURATION; PATHOGENESIS; PHARMACODYNAMICS; PHARMACOGENETICS; PREGNANCY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SIDE EFFECT; STOMACH CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOGLOBULIN G; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; VENTRICULAR FUNCTION, LEFT;

EID: 79959606211     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0035     Document Type: Article

References (52)

1. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001;344:783-792.
3. Burstein HJ, Keshaviah A, Baron AD et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 2007;110: 965-972.
4. Infante JR, Yardley DA, Burris HA 3rd et al. Phase II trial of weekly do-cetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clin Breast Cancer 2009;9: 23-28.
5. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274.
6. Schaller G, Fuchs I, Gonsch T et al. Phase II study of capecitabine plus tras-tuzumab in human epidermal growth factor receptor 2 overexpressing met-astatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007;25:3246-3250.
7. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-7826.
8. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: From early scientific development to foundation of care. Am J Clin Oncol 2010;33:186-195.
9. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N EnglJMed 2005;353: 1673-1684.
10. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36.
11. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastricorgastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
12. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.
13. Vocaturo A, Novelli F, Benevolo M et al. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: A sensitive and practical method in the trastuzumab era. The Oncologist 2006;11:878-886.
14. Damen CW, Speijer H, Hermens WT et al. The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry. Anal Biochem 2009;393:73-79.
15. Pant S, Landon MB, Blumenfeld M et al. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 2008;26:1567-1569.
16. Bader AA, Schlembach D, Tamussino KF et al. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 2007;8:79-81.
17. Candelaria M, Taja-Chayeb L, Arce-Salinas C et al. Genetic determinants of cancer drug efficacy and toxicity: Practical considerations and perspectives. Anticancer Drugs 2005;16:923-933.
18. Beauclair S, Formento P, Fischel JL et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 2007;18:1335-1341.
19. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-1796.
20. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial. J Clin Oncol 2007;25: 3859-3865.
21. Tan-Chiu E, Yothers G, Romond E et al. Assessmentofcardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819.
22. Bria E, Cuppone F, Fornier M et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: The dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008;109:231-239.
23. Russell SD, Blackwell KL, Lawrence J et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosph-amide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010;28:3416-3421.
24. Procter M, Suter TM, deAzambuja E et al. Longer-term assessment of tras-tuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010;28:3422-3428.
25. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
26. Morris PG, Hudis CA. Trastuzumab-related cardiotoxicity following an-thracycline-based adjuvant chemotherapy: How worried should we be? J Clin Oncol 2010;28:3407-3410.
27. Wadhwa D, Fallah-Rad N, Grenier D et al. Trastuzumab mediated cardio-toxicity in the setting of adjuvant chemotherapy for breast cancer: A retrospective study. Breast Cancer Res Treat 2009;117:357-364.
28. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumabinmetastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-4115.
29. Camenisch TD, Schroeder JA, Bradley J et al. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med 2002;8:850-855.
30. Lee KF, Simon H, Chen H et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995;378:394-398.
31. Ozcelik C, Erdmann B, Pilz B et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002;99:8880-8885.
32. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-465.
33. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995;378:386-390.
34. Uray IP, Connelly JH, Thomàzy V et al. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant 2002;21:771-782.
35. Fuchs IB, Landt S, Bueler H et al. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res Treat 2003;82:23-28.
36. Perik PJ, Lub-De Hooge MN, Gietema JA et al. Indium-111-labeled tras-tuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24:2276-2282.
37. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotox-icity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910-3916.
38. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immuno-therapy in metastatic breast cancer. Oncology 2001;61(suppl 2):58-66.
39. Pandolfi PP. Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 2004;351:2337-2338.
40. Park BH, Davidson NE. PI3 kinase activation and response to trastuzumab therapy: What's neu with Herceptin resistance? Cancer Cell 2007;12:297-299.
41. Harris LN, You F, Schnitt SJ et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007;13:1198-1207.
42. Moasser MM. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-6487.
43. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
44. Blackwell KL, Pegram MD, Tan-Chiu E et al. Single-agent lapatinib for HER2-overexpressing advanced ormetastatic breast cancer that progressed on first-or second-line trastuzumab-containing regimens. Ann Oncol 2009; 20:1026-1031.
45. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-543.
46. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
47. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapa-tinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-1130.
48. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28:1301-1307.
49. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-2704.
50. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastu-zumab therapy. J Clin Oncol 2010;28:1138-1144.
51. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-5537.
52. Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786-2792.